OSR Health Inc Dossier - Source-backed chat

OSR Health Inc

OSRHNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.67

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.23Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $8.2M

Enterprise Value $7.2M

Shares Outstanding 35.1M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

OSR Health Inc (NASDAQ:OSRH) is a global healthcare holding company at a major valuation inflection point. The company's current market capitalization sits below the contractually guaranteed cash value of its single $15 million Put Option against BCM Europe AG, which becomes exercisable on October 29, 2026. Furthermore, its lead asset VXM01 (an oral cancer immunotherapy) has been out-licensed in a landmark transaction with up to $815 million in potential milestones, carrying an independent risk-adjusted NPV of $94 million. To address the valuation disconnect and reward long-term holders without resorting to a dilutive reverse stock split, the Board has established a novel Shareholder Loyalty CVR Program. This program distributes Contingent Value Rights that award up to 5 additional shares per original share held if sustained price milestones between $2.00 and $5.00 are met over a 12-month period. Backed by strategic assets like Woori IO's non-invasive glucose monitoring platform, OSRH presents an asymmetric risk-reward profile for micro-cap healthcare investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$10.00

High · most bullish analyst$10.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.3015%

Stockholders reject the authorized share increase, delaying or invalidating the Shareholder Loyalty CVR Program. BCM Europe AG or its strategic backer defaults or delays settlement of the $15 million Put Option in October 2026, leading to litigation and severe cash constraints. VXM01 clinical development faces regulatory hurdles, delaying milestone payments, and the stock remains highly volatile, trading near its historical lows.

Base CaseCentral scenario

$10.0060%

Matches the consensus mean

OSR Health successfully obtains stockholder approval to increase authorized shares at the August 7, 2026 meeting and implements the CVR program. The stock stabilizes and begins to climb, triggering the Tier 1 ($2.00) and Tier 2 ($3.00) milestones, rewarding loyal shareholders with additional shares. The $15 million Put Option is successfully exercised in late 2026, securing the company's financial position and validating the contract's backing. Emerging Growth Research maintains a 12-month price target of $10.00 based on these de-risking events.

Bull CaseUpside scenario

$10.5025%

The Shareholder Loyalty CVR Program successfully triggers all four price milestones over 12 months, driving the stock price to $5.00 or higher. The $15 million Put Option is fully exercised and settled on or shortly after October 29, 2026, providing a massive non-dilutive cash runway. Concurrently, VXM01 clinical milestones are met, triggering early-stage milestone payments from the $815 million licensing agreement, while Woori IO secures FDA clearance or strategic commercial partnerships with Samsung, unlocking substantial hidden portfolio value.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Significant valuation disconnect where the entire market cap is lower than the $15 million Put Option exercisable on October 29, 2026.
High-value out-licensing transaction for VXM01 with up to $815 million in potential milestones and a $94 million risk-adjusted NPV.
Innovative Shareholder Loyalty CVR Program offering up to 6x position multiplier as an alternative to a reverse stock split.
Strategic upside from Woori IO's non-invasive continuous glucose monitoring platform, backed by Samsung engagements.

Key Investment Risks

High historical financial losses, with a net loss of $12.2 million in FY 2025 and $2.93 million in Q1 2026.
Substantial shareholder dilution, with shares outstanding increasing significantly over the past year.
Counterparty risk regarding BCM Europe AG's capacity to settle the $15 million Put Option upon exercise.
Regulatory and clinical trial risks inherent to early-stage biotechnology and medical device portfolios.

Thesis Invalidation Triggers

Failure to obtain stockholder approval for the authorized share increase at the August 7, 2026 Annual Meeting.
Default or failure to settle by BCM Europe AG on the $15 million Put Option after October 29, 2026.
Termination or material negative modification of the VXM01 out-licensing agreement.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.